October 2014
Merck KGaA acquiring Sigma-Aldrich to enhance position in increasingly attractive life-sciences market...
by Jeffrey Bouley

October 2014
Mayo Clinic and IBM to apply Watson to clinical trial enrollment...
by Kelsey Kaustinen

October 2014
Blueprint Medicines announces discovery of novel oncology drug targets...
by Jeffrey Bouley

September 2014
RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by FDA and EMA ...
by Lloyd Dunlap

September 2014
Oral treatment for spinal muscular atrophy appears effective in mice ...
by Zack Anchors

September 2014
Scripps Research Institute scientists find that cancer drug rapamycin may help bypass blood stem cell defenses...
by Lori Lesko



 

ASHG 2014 Preview:
Shining a light on human genetics in sunny San Diego
Reportedly the largest human genetics meeting and exposition in the world, the 64th Annual Meeting of the American Society of Human Genetics (ASHG) from Oct. 18 to 22 will cover ethics in genomics, advances in sequencing and much else, attracting more than 6,500 scientific attendees and featuring well over 200 exhibiting companies. Find out more about the show, whether to get ready for your own attendance or to determine whether you should go. Read more
 

And from ISSCR 2014, here are  reports from the field by DDNews Features Editor Randall C Willis ...
 
"Taking stem cells from bench to business"
"Building a better model"
"Shifting stem cell regulatory landscape"
"Patients' growing impatience for cell therapies"

 Our 2015 Media Kit is now available
 
 

 
Your gateway to the latest oncology news, trends and resources


October 2014
The ability to create isogenic cell lines in which the genome editing event is the sole differentiator between the phenotypes of two cells is a powerful tool. Despite all the recent developments and improvements in targeting platforms, certain challenges remain, and the role played by the choice of cell line in order to achieve success cannot be overstated... [ more ]
by Eric Rhodes & Dr. Jon Moore

October 2014
In an era of "publish or perish," combined with "fund or perish," we may be moving toward an era in which peer review is no longer up to the task, and we end up with too many journals and too little rigor.. [ more ]
by Peter T. Kissinger

October 2014
The effort to reduce obesity (and to profit from that effort) isn’t anything new, but based on my email inbox recently, perhaps we’re about to enter into an era of blockbuster weight-management medications. For the moment, however, we’re at the early stages of any such race, and it looks like Novo Nordisk and Orexigen are fighting for the strong start out of the gate... [ more ]
by Jeffrey Bouley